ECO 2026
12 - 15 May 2026
CagriSema 2.4 mg/2.4 mg Improves Metabolic Syndrome in Adults With Overweight or Obesity, Without Type 2 Diabetes: A Post Hoc Analysis of REDEFINE 1
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.